Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9017334 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL17204105 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL13279250 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL7702846 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL6536277 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL7705328 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL25175260 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL21724210 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL21724206 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 | |
| SCHEMBL21724437 | 1.00 | NOD1 (0.65) | NOD1SLC6A5EPHX2FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| US-20010055576-A1 | CLEANSING COMPOSITION | HONDA SHINKICHI (JP) | 2001-12-27 | — | — | US | claimed |
| CN-118829647-A | Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof | 詹森药业有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-116419750-A | Improved pharmaceutical formulations of GLP-1 receptor agonists | 西普鲁梅有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023058469-A1 | COSMETIC COMPOSITION | 株式会社 資生堂 | 2023-04-13 | — | — | WO | disclosed |
| CN-109069475-B | Fast acting botanical pharmaceutical compounds and nutritional supplements | 受体控股公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3883595-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | Receptor Holdings, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-111971027-A | Oral formulations and treatments for parathyroid hormone analogs | 奥孟亚股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3672608-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3672610-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019071211-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| CN-109069475-A | Snap action plant pharmaceutical compound and nutritional supplement | 受体生命科学公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2018175992-A1 | RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS | RECEPTOR LIFE SCIENCES (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018129097-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018102029-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2017185038-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2017-10-26 | — | — | WO | disclosed |
| CN-106794252-A | Pharmaceutical formulations for oral delivery of peptide or protein drugs | 塞浦路迈德有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| US-6350783-B2 | CLEANING COMPOUND IS A N-LONG CHAIN ACYLAMINO ACID OR SALTS THEREOF, WHERE LONG CHAIN IS COCONUT OIL FATTY ACID OR PALM KERNEL OIL FATTY ACID, AND THE AMINO ACID IS GLUTAMINE OR ASPARAGINE | KYOWA HAKKO KOGYO (JP) | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010055576-A1 | CLEANSING COMPOSITION | ELOVL1, ELOVL5, SGMS1 | NOD1 3867/4885SLC6A5 3646/4885EPHX2 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.